Cite
HARVARD Citation
Vest, J. et al. (n.d.). P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement. Canadian journal of neurological sciences. p. S20. [Online].